Inaccurate Clinical Stage Is Common and Associated With Poor Survival in Patients With Lung Cancer
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Inaccurate clinical staging affects one-third of lung cancer patients undergoing surgery, leading to poorer survival outcomes. Improving staging accuracy is crucial for better patient prognosis and treatment planning.
Area Of Science
- Oncology
- Thoracic Surgery
- Cancer Staging
Background
- Accurate clinical staging is vital for lung cancer treatment and prognosis.
- Discrepancies between clinical and pathologic staging can impact patient outcomes.
- Understanding factors influencing staging accuracy is essential for quality improvement.
Purpose Of The Study
- To determine the rate of inaccurate clinical staging in non-small cell lung cancer (NSCLC) patients.
- To identify risk factors associated with clinical staging inaccuracy.
- To evaluate the impact of staging inaccuracy on overall survival in NSCLC patients.
Main Methods
- Retrospective cohort study of 255,598 NSCLC patients from the National Cancer Database (2004-2020).
- Patients categorized based on accuracy of clinical stage versus pathologic stage post-surgical resection.
- Multivariate models analyzed risk factors for inaccuracy and association with overall survival.
Main Results
- 33.1% of patients (84,543) had inaccurate clinical staging.
- Higher T-category, N-category, increased lymph nodes evaluated, and extensive resection were risk factors for inaccuracy.
- Robotic surgery was associated with lower inaccuracy rates (OR=0.89).
- Inaccurate staging significantly correlated with worse overall survival (5-year survival: 67.5% accurate vs. 55.4% inaccurate; HR=1.3).
Conclusions
- Clinical staging inaccuracy is prevalent, affecting one-third of surgically treated lung cancer patients.
- Both understaging and overstaging are linked to inferior survival.
- Quality improvement efforts should prioritize enhancing the accuracy of clinical lung cancer staging.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...